首页(Home)
品牌专区(Brands-parters)
//自动完成提示
function beginSearch() {
if (document.getElementById("Keyword").value.replace(/(^\s*)|(\s*$)/g, "").length > 2) {
$("#divMsg").html("");
var tbSearch = document.getElementById("Keyword").value;
var div_msg = document.getElementById("divMsg");
div_msg.style.display = "block";
$.ajax({
type: "post",
dataType: "json", //数据格式:JSON
url: "/tools/submit_ajax.ashx?action=zhitishi",
data: { father: tbSearch },
async: false,
success: function (data) {
var str = "";
var str1 = "";
var str2 = "";
var str3 = "";
var SupplyType = data.SupplyType; //供应品类列表
var Brands = data.Brands; //品牌列表
var ProductStyle = data.ProductStyle; //产品列表
var str0 = "";
if (SupplyType != null && SupplyType != "") {
str0 += " 美国Dicerna www.dicerna.com Dicer Substrate Technology is a next generation RNAi approach that results in greater potency, longer duration of action and enhanced delivery potential, differentiating it from other RNAi approaches. Dicerna believes that its Dicer Substrate Technology is based on intellectual property that is both broadly enabling and distinct from other IP in the field. The company’s internal research and development program is focused in oncology. In addition, Dicerna has active research and development programs focused on the therapeutic areas of oncology, endocrinology, immunology and inflammation with its pharmaceutical partners. Dicerna has two major alliances with global pharmaceutical companies, as well as other collaborations, and will continue to build on this momentum to advance its research and development efforts. Specifically, in 2010, Dicerna announced a major alliance with Kyowa Hakko Kirin for DsiRNA pharmaceuticals and drug delivery systems, focused on oncology, immunology and inflammation, as well as an exclusive research collaboration with Ipsen to develop novel conjugates of DsiRNA molecules and Ipsen’s peptide targeting vectors in the therapeutic areas of oncology and endocrinology. Dicerna was founded in 2007, based on the discoveries and intellectual property of scientific co-founders John Rossi and Mark Behlke. The company has raised approximately $50 million in venture capital funding from its investors Abingworth, Domain Associates, Oxford Bioscience Partners, Skyline Ventures and SR One. Dicerna is based in Watertown, Mass.供应分类";
$.each(SupplyType, function () {//遍历Specification
str0 += "";
});
}
if (ProductStyle != null && ProductStyle != "") {
str1 += "产品分类";
$.each(ProductStyle, function () {//遍历ProductType
str1 += "";
});
}
if (Brands != null && Brands != "") {
str2 = "品牌";
$.each(Brands, function () {//遍历Brands
str2 += "";
});
}
str = str0 + str2 + "";
$("#divMsg").html(str);
}
});
}
else if (document.getElementById("Keyword").value.replace(/(^\s*)|(\s*$)/g, "").length == 0) {
var div_msg = document.getElementById("divMsg");
div_msg.style.display = "none";
div_msg.innerHTML = "";
}
}
RNAi药物研发商 DsiRNA
Dicerna Pharmaceuticals is a private, venture-backed RNA interference (RNAi) company developing novel therapeutic agents and related drug delivery systems in multiple disease areas based on its proprietary Dicer Substrate Technology™ platform and Dicer Substrate siRNA (DsiRNA) molecules.
